Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective

References

• Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nature Rev Rheumatol 2017;13:731–41
   PubMed Web of Science ®Google Scholar
• Taurog JD. The spondyloarthritides. In: Fauci ASLC, editor. Harrison’s rheumatology. 16th ed. New York: McGraw-Hill; 2005. p 139–55
   Google Scholar
• Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol 2014;28:663–72
   PubMed Web of Science ®Google Scholar
• Stolwijk C, van Tubergen A, Castillo-Ortiz JD, et al. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:65–73
   PubMed Web of Science ®Google Scholar
• Heuft-Dorenbosch L, Vosse D, Landewe R, et al. Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. J Rheumatol 2004;31:1779–84
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;390:73–84
   PubMed Web of Science ®Google Scholar
• Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep 2008;10:371–8
   PubMedGoogle Scholar
• Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology 2014;53:650–7
   PubMed Web of Science ®Google Scholar
• Barnabe C, Jones CA, Bernatsky S, et al. Inflammatory arthritis prevalence and health services use in the first nations and non-first nations populations of Alberta, Canada. Arthritis Care Res 2017;69:467–74
   Web of Science ®Google Scholar
• Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006;78:4–11
   PubMedGoogle Scholar
• Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289–95
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91
   Web of Science ®Google Scholar
• Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: specific management recommendations. J Rheumatol 2015;42:665–81
   Google Scholar
• Novartis Pharmaceuticals Canada Inc. Cosentyx® Product Monograph. Canada: Novartis; 2016. Available at: http://www.novartis.ca [Last accessed July 2017]
   Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534–48
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis 2017;76:571–92
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017;19:285
   Google Scholar
• Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther 2018 Aug 18. doi:10.1007/s40744-018-0123-5. PubMed PMID: 30121827; eng 
   Web of Science ®Google Scholar
• Maksymowych WP, Strand V, Baeten D, et al., editors. Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab for up to 52 weeks using a matching-adjusted indirect comparison (P147). 10^th International Congress on Spondyloarthritides. September 15–17, 2016, Ghent, Belgium
   Google Scholar
• Clinicaltrials.gov. Effect of secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar). 2017. Available at: https://ClinicalTrials.gov/show/NCT03259074 [Last accessed January 2018]
   Google Scholar
• Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther 2016;16:711–22
   PubMed Web of Science ®Google Scholar
• Keat A, Barkham N, Bhalla A, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005;44:939–47
   Google Scholar
• NICE. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: NICE Technology Appraisal 383. UK: NICE; 2016. Available at: http://www.nice.org.uk/TA383 [Last accessed July 2017]
   Google Scholar
• NICE. Golimumab for the treatment of ankylosing spondylitis. NICE Technology Appraisal 233. UK: NICE; 2011. Available at: https://www.nice.org.uk/guidance/ta233 [Last accessed July 2017]
   Google Scholar
• CADTH. Canada expert drug advisory committee final recommendation and reconsideration and reasons for recommendation. Canada: CADTH; 2007 Available at: https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Humira_Resubmission_June-27-2007.pdf2007 [Last accessed October 4, 2018]
   Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91
   PubMed Web of Science ®Google Scholar
• Baeten DPM, Strand V, McInnes I, et al. Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus currently licensed biologics from a network meta-analysis. Ann Rheum Dis 2016;75(suppl 2):809–810
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE decision support unit technical support documents. A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London: National Institute for Health and Care Excellence (NICE); 2014
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index. Ottawa, Ontario: Government of Canada; 2016. Available at: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx2016 [Last accessed May 5, 2016]
   Google Scholar
• Corbett MSM, Jhunti G, Rice S, et al. TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233). York: CRD/CHE Technology Assessment Group (Centre for Review and Dissemination/Centre for Health Economics) University of York; 2014
   Google Scholar
• Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess 2016;20:1–334, v–vi
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Consumer Price Index, historical summary (1996 to 2017) [Internet]. Government of Canada; Ottawa, Ontario; 2018. Available at: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ46a-eng.htm [Last accessed August 19, 2016]
   Google Scholar
• Statistics Canada. Probability of dying by age and sex, Canada, 2007/2009 period. Ottawa, Ontario: Government of Canada; 2013. Available at: http://www.statcan.gc.ca/pub/91-209-x/2013001/article/11785/c-g/desc/desc02-eng.htm [Last accessed August19, 2016]
   Google Scholar
• CADTH Guidelines for the Economic Evaluation of Health Technologies: Canada; 2017. Available at: https://www.cadth.ca/sites/default/files/pdf/economic_guidelines_worked_example.pdf 2017 [Last accessed October 4, 2018]
   Google Scholar
• McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation [Review]. Health Technol Assess 2007;11:1–158, iii–iv
   PubMed Web of Science ®Google Scholar
• NICE. NICE Technology Appraisal - Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors [TA 407]. UK: NICE; 2016. Available at: https://www.nice.org.uk/guidance/ta407 [Last accessed April 1, 2018]
   Google Scholar
• Sarioz F, Ozdemir O, Direk S, et al. Secukinumab is dominant vs. TNF-inhibitors in the treatment of active ankylosing spondylitis: results from a Turkish cost-effectiveness model. Value Health 2017;20:A534
   Web of Science ®Google Scholar
• Romero Prada ME, Roa Cardenas NC, Serrano GY, et al. Cost-utility analysis of secukinumab use versus tnf-a inhibitors, in patients with ankylosing spondilytis. Value Health 2017;20:A938–A939
   Web of Science ®Google Scholar
• Marzo-Ortega H, Halliday A, Jugl S, et al. The cost-effectiveness of secukinumab versus tumour necrosis factor a inhibitor biosimilars for ankylosing spondylitis in the UK. Rheumatology 2017;56:ii92
   Google Scholar
• Emery P, Van Keep M, Beard SM, et al. Cost-effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Value Health 2017;20:A534
   Web of Science ®Google Scholar
• Djambazov S, Vekov T. Incremental cost-effectiveness analysis of biological drug therapies for the treatment of ankylosing spondylitis in Bulgaria, 2016. Value Health 2017;20:A221
   Google Scholar
• Fedyaev D, Derkach EV. Cost-effectiveness analysis of different biologic agents for ankylosing spondylitis treatment in Russia. Value Health 2016;19:A539
   Web of Science ®Google Scholar
• Braun JBX, Deodhar AA, Poddubnyy D, et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis [abstract]. Arthritis Rheumatol 2017;69
   Google Scholar
• Baraliakos X, Braun J, Deodhar A, et al. SAT0268 secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Ann Rheum Dis 2018;77(Suppl 2):997–8
   Google Scholar
• Maksymowych W, Strand V, Baeten D, et al. OP0114 secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab using a matching-adjusted indirect comparison. Ann Rheum Dis 2016;75(Suppl 2):98
   Google Scholar
• Chiva-Razavi S, Jain M, Graham CN, et al. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis: a Canadian perspective. Value Health 2017;20:A533–A534
   PubMed Web of Science ®Google Scholar